Table 5 Comparisons of clinical characteristics between SCE and non-SCE patients

Age (years, IQR)

66 (55–75)

61 (51–68)

0.038^*

Male (n, %)

26 (61.9%)

34 (58.6%)

0.741^†

CHA₂DS₂-VASc score (points, IQR)

2 (1–3)

1 (1–3)

0.002^*

MoCA score

 Baseline (points, IQR)

26.5 (21.8–28.0)

26.0 (22.0–27.0)

0.888^*

 Post procedure (points, IQR)

26.0 (22.0–28.0)

26.0 (23.0–28.3)

0.572^*

 3 months (points, IQR)

26.0 (24.0–29.3)

27.5 (24.0–28.3)

0.743^*

Ablation strategy

 HPSD strategy (n, %)

22 (52.4%)

28 (48.3%)

0.685^†

 Conventional approach (n,%)

20 (47.6%)

30 (51.7%)

AF classification

 Paroxysmal (n, %)

19 (45.2%)

40 (69%)

0.017^†

 Persistent (n, %)

23 (54.8%)

18 (31%)

0.020^†

Echocardiography

 LAD (mm, mean ± SD)

39.3 ± 4.9

37.4 ± 4.5

0.047^¶

 LVEF (%, IQR)

66.0 (63.8–71.3)

66.0 (61.8–71.3)

0.376^*

Comorbidities

 Hypertension (n, %)

28 (66.7%)

19 (32.8%)

 < 0.001^†

 Coronary artery disease (n, %)

14 (33.3%)

9 (15.5%)

0.037^†

 Diabetes mellitus (n, %)

6 (14.3%)

7 (12.1%)

0.745^†

 Heart failure (n, %)

0

4 (7.0%)

0.137^‡

 Stroke/TIA (n, %)

6 (14.3%)

8 (13.8%)

0.944^†

 Hyperlipidemia (n, %)

7 (16.7%)

17 (29.3%)

0.144^†

Laboratory test

 Creatinine (mmol/L, IQR)

71.1 (64.3–85.6)

70.1 (61.8–86.0)

0.992^*

 NT-proBNP level (pg/ml, IQR)

415.3 (123.8–1008.1)

219.1 (107.0–766.3)

0.230^*